UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 342

Sortiert nach

ERBB receptors and cancer: the complexity of targeted inhibitors

Nature reviews. Cancer, 2005-05, Vol.5 (5), p.341-354

2005

Link zum Volltext

Verfügbarkeit prüfen

Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells

Cell reports (Cambridge), 2018-12, Vol.25 (11), p.3047-3058.e4

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

Journal of clinical oncology, 2009-06, Vol.27 (16), p.2630-2637

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2008-04, Vol.26 (10), p.1588-1595

2008

Link zum Volltext

Verfügbarkeit prüfen

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2008-04, Vol.26 (10), p.1603-1610

2008

Link zum Volltext

Verfügbarkeit prüfen

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition

Molecular cancer therapeutics, 2009-04, Vol.8 (4), p.742-753

2009

Link zum Volltext

Verfügbarkeit prüfen

Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data

Journal of clinical oncology, 2008-04, Vol.26 (10), p.1596-1602

2008

Link zum Volltext

Verfügbarkeit prüfen

The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation

Cell, 2005-03, Vol.120 (6), p.747-759

2005

Link zum Volltext

Verfügbarkeit prüfen

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

Clinical cancer research, 2009-03, Vol.15 (5), p.1612-1622

2009

Link zum Volltext

Verfügbarkeit prüfen

Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer

Clinical cancer research, 2005-07, Vol.11 (14), p.5319-5328

2005

Link zum Volltext

Verfügbarkeit prüfen

Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors

Molecular cancer therapeutics, 2008-05, Vol.7 (5), p.1237-1245

2008

Link zum Volltext

Verfügbarkeit prüfen

AKT/mTOR Pathway Activation and BCL-2 Family Proteins Modulate the Sensitivity of Human Small Cell Lung Cancer Cells to RAD001

Clinical cancer research, 2009-02, Vol.15 (4), p.1277-1287

2009

Link zum Volltext

Verfügbarkeit prüfen

RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR

Cancer research (Chicago, Ill.), 2008-06, Vol.68 (11), p.4183-4191

2008

Link zum Volltext

Verfügbarkeit prüfen

The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells

Cancer research (Chicago, Ill.), 2007-07, Vol.67 (14), p.6956-6964

2007

Link zum Volltext

Verfügbarkeit prüfen

Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin)

JCI insight, 2021-09, Vol.6 (18)

2021

Link zum Volltext

Verfügbarkeit prüfen

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition

Molecular cancer therapeutics, 2005-01, Vol.4 (1), p.101-112

2005

Link zum Volltext

Verfügbarkeit prüfen

Syrosingopine sensitizes cancer cells to killing by metformin

Science advances, 2016-12, Vol.2 (12), p.e1601756-e1601756

2016

Link zum Volltext

Verfügbarkeit prüfen

Building Rule of Law in the Arab World: Tunisia, Egypt, and Beyond

1, 2015

Link zum Volltext

Verfügbarkeit prüfen

Optimal targeting of the mTORC1 kinase in human cancer

Current opinion in cell biology, 2009-04, Vol.21 (2), p.219-229

2009

Link zum Volltext

Verfügbarkeit prüfen

PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel

Clinical cancer research, 2008-06, Vol.14 (12), p.3993-4001

2008

Link zum Volltext

Verfügbarkeit prüfen

The fibroblast growth factor receptor inhibitor, derazantinib, has strong efficacy in human gastric tumor models and synergizes with paclitaxel in vivo

Anti-cancer drugs, 2023-04, Vol.34 (4), p.532

2023

Link zum Volltext

Verfügbarkeit prüfen

EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis

Oncotarget, 2020-02, Vol.11 (8), p.759-774

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours

British journal of cancer, 2020-10, Vol.123 (9), p.1360-1369

2020

Link zum Volltext

Verfügbarkeit prüfen

The ErbB signaling network: receptor heterodimerization in development and cancer

The EMBO journal, 2000-07, Vol.19 (13), p.3159-3167

2000

Link zum Volltext

Verfügbarkeit prüfen

The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells

Molecular cancer therapeutics, 2016-11, Vol.15 (11), p.2740-2749

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 342

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(293)
Mit Volltextzugriff
(303)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

ERBB receptors and cancer: the complexity of targeted inhibitors

Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition

Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data

The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer

Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors

AKT/mTOR Pathway Activation and BCL-2 Family Proteins Modulate the Sensitivity of Human Small Cell Lung Cancer Cells to RAD001

RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR

The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells

Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin)

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition

Syrosingopine sensitizes cancer cells to killing by metformin

Building Rule of Law in the Arab World: Tunisia, Egypt, and Beyond

Optimal targeting of the mTORC1 kinase in human cancer

PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel

The fibroblast growth factor receptor inhibitor, derazantinib, has strong efficacy in human gastric tumor models and synergizes with paclitaxel in vivo

EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis

Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours

The ErbB signaling network: receptor heterodimerization in development and cancer

The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells

Suchergebnisse filtern